Epirubicin for breast cancer may cause considerable venous sclerosis
نویسندگان
چکیده
منابع مشابه
Epirubicin for breast cancer may cause considerable venous sclerosis.
lecting data, conducting the analysis, and drafting the original article. All his coauthors helped to develop the study design, interpret the results, draft the manuscript, and revise the article for intellectual content. All authors have read and approved the final version. SGM is the guarantor. Funding: This project was supported by an operating grant from the Canadian Institutes of Health Re...
متن کاملDocetaxel and epirubicin in advanced breast cancer.
In an International Breast Cancer Study Group phase I/II program, 70 patients with advanced breast cancer received up to eight courses of 75 mg/m2 docetaxel combined with 90 mg/m(2) epirubicin, every 3 weeks. G-CSF was not administered prophylactically. Grade 4 neutropenia occurred in 88% of cycles that were not supported by G-CSF. However, febrile neutropenia affected only 24% of cycles. It oc...
متن کاملPaclitaxel plus epirubicin in advanced breast cancer.
This phase I-II study aimed to determine the maximum tolerated dose (MTD) of paclitaxel (Taxol), infused over 3 hours, when combined with a fixed dose (90 mg/m2) of epirubicin. Other aims were to investigate the combination's plasma pharmacokinetics, toxicity, and activity in 50 patients with previously untreated metastatic breast cancer, as well as its ability to mobilize peripheral blood stem...
متن کاملChemotherapy for breast cancer during pregnancy: is epirubicin safe?
The co-occurrence of cancer and pregnancy is becoming more frequent, given the trend for women to postpone childbearing [1]. As a consequence, the collection of more information about the effects of anticancer agents during pregnancy is useful to improve the existing guidelines. The most frequent solid tumour observed in pregnant women is breast cancer [1]. Among the drugs potentially active in...
متن کاملAdjuvant chemotherapy for early breast cancer: optimal use of epirubicin.
Anthracyclines are central components of adjuvant combination chemotherapy regimens for early breast cancer. Epirubicin is underutilized for this indication in the United States, where it was approved by the Food and Drug Administration in 1999, compared to Europe and Canada, where it gained approval in 1980. Use of epirubicin offers advantages in specific treatment settings and patient subsets...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 2005
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.38574.659225.79